1-10 of 10
Xiang Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

Available to Purchase
Anthony R. Cillo, Elina Mukherjee, Nathanael G. Bailey, Sayali Onkar, Jessica Daley, Claudia Salgado, Xiang Li, Dongyan Liu, Sarangarajan Ranganathan, Melissa Burgess, John Sembrat, Kurt Weiss, Rebecca Watters, Tullia C. Bruno, Dario A.A. Vignali, Kelly M. Bailey
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4968–4982.
https://doi.org/10.1158/1078-0432.CCR-22-1471
Published: 14 November 2022
View articletitled, Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Open the PDF for Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks in another window
Includes: Supplementary data
Journal Articles

Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Available to Purchase
Chunmeng Wang, Yang Liu, Liang Dong, Xiang Li, Qingming Yang, Malcolm V. Brock, Qian Mei, Jiejie Liu, Meixia Chen, Fengxia Shi, Miao Liu, Jing Nie, Weidong Han
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2782–2791.
https://doi.org/10.1158/1078-0432.CCR-21-0133
Published: 15 May 2021
View articletitled, Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Open the PDF for Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy in another window
Includes: Supplementary data
Journal Articles

Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma

Free
Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindong Dai, Yali Shen, Zhiping Li, Jiyan Liu, Junru Chen, Jiandong Liu, Zhipeng Wang, Xudong Zhu, Yuchao Ni, Dan Qin, Ling Yang, Yuntian Chen, Qiang Wei, Xiang Li, Qiao Zhou, Haojie Huang, Jin Yao, Ni Chen, Hao Zeng
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (6): 1734–1743.
https://doi.org/10.1158/1078-0432.CCR-20-3788
Published: 15 March 2021
View articletitled, Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
Open the PDF for Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial

Available to Purchase
Qian Mei, Wenying Zhang, Yang Liu, Qingming Yang, John E.J. Rasko, Jing Nie, Jiejie Liu, Xiang Li, Liang Dong, Meixia Chen, Yan Zhang, Lu Shi, Huitao Wu, Weidong Han
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4521–4530.
https://doi.org/10.1158/1078-0432.CCR-20-0514
Published: 01 September 2020
View articletitled, Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Open the PDF for Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Free
Jianming Xu, Yuxian Bai, Nong Xu, Enxiao Li, Buhai Wang, Jin Wang, Xiang Li, Xin Wang, Xianglin Yuan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (17): 4542–4550.
https://doi.org/10.1158/1078-0432.CCR-19-3561
Published: 01 September 2020
View articletitled, Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Open the PDF for Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy

Free
Xiang Li, Yan Zhang, Meixia Chen, Qian Mei, Yang Liu, Kaichao Feng, Hejin Jia, Liang Dong, Lu Shi, Lin Liu, Jing Nie, Weidong Han
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6031–6043.
https://doi.org/10.1158/1078-0432.CCR-17-1201
Published: 12 October 2017
View articletitled, Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy
Open the PDF for Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy in another window
Includes: Supplementary data
Journal Articles

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Free
Chun-Meng Wang, Zhi-Qiang Wu, Yao Wang, Ye-Lei Guo, Han-Ren Dai, Xiao-Hui Wang, Xiang Li, Ya-Jing Zhang, Wen-Ying Zhang, Mei-Xia Chen, Yan Zhang, Kai-Chao Feng, Yang Liu, Su-Xia Li, Qing-Ming Yang, Wei-Dong Han
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1156–1166.
https://doi.org/10.1158/1078-0432.CCR-16-1365
Published: 28 February 2017
View articletitled, Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Open the PDF for Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway

Free
Qian Mei, Xiang Li, Kang Zhang, Zhiqiang Wu, Xiaolei Li, Yuanguang Meng, Mingzhou Guo, Guangbin Luo, Xiaobing Fu, Weidong Han
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (2): 575–586.
https://doi.org/10.1158/1078-0432.CCR-16-0303
Published: 15 January 2017
View articletitled, Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway
Open the PDF for Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway in another window
Includes: Supplementary data
Journal Articles

ShRNA-Targeted MAP4K4 Inhibits Hepatocellular Carcinoma Growth

Free
An-Wen Liu, Jing Cai, Xiang-Li Zhao, Ting-Hui Jiang, Tian-Feng He, Hua-Qun Fu, Ming-Hua Zhu, Shu‐Hui Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 710–720.
https://doi.org/10.1158/1078-0432.CCR-10-0331
Published: 15 February 2011
View articletitled, ShRNA-Targeted MAP4K4 Inhibits Hepatocellular Carcinoma Growth
Open the PDF for ShRNA-Targeted MAP4K4 Inhibits Hepatocellular Carcinoma Growth in another window
Includes: Supplementary data
Journal Articles

Generation of PRL-3- and PRL-1-Specific Monoclonal Antibodies as Potential Diagnostic Markers for Cancer Metastases

Free
Jie Li, Ke Guo, Vicki Wei Chyi Koh, Jing Ping Tang, Bin Qi Gan, Hong Shi, Hui Xiang Li, Qi Zeng
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (6): 2195–2204.
https://doi.org/10.1158/1078-0432.CCR-04-1984
Published: 23 March 2005
View articletitled, Generation of PRL-3- and PRL-1-Specific Monoclonal Antibodies as Potential Diagnostic Markers for Cancer Metastases
Open the PDF for Generation of PRL-3- and PRL-1-Specific Monoclonal Antibodies as Potential Diagnostic Markers for Cancer Metastases in another window